Literature DB >> 28711192

Predictors of anxiety in early-stage Parkinson's disease - Results from the first two years of a prospective cohort study.

Sonja Rutten1, Peter M van der Ven2, Daniel Weintraub3, Gregory M Pontone4, Albert F G Leentjens5, Henk W Berendse6, Ysbrand D van der Werf7, Odile A van den Heuvel8.   

Abstract

AIM: Anxiety has a negative impact on daily functioning and quality of life in patients with Parkinson's disease (PD). This study aims at assessing which sociodemographic and clinical characteristics predict the course of anxiety in early PD.
METHODS: The participants of this two-year prospective cohort study were recently diagnosed PD patients not receiving psychiatric medications or dopamine replacement therapy at baseline. Assessments were performed annually after baseline. The primary outcome measure was anxiety, as measured with the State-Trait Anxiety Inventory (STAI). Covariates were age, gender, family history, striatal dopamine transporter binding ratios, and severity of motor and non-motor features of PD at baseline. Data were analyzed using a mixed model analysis.
RESULTS: Inclusion criteria were met by 306 subjects. An increase in STAI total score was predicted by older age, lower score on the Montreal Cognitive Assessment, and the presence of a probable REM-sleep behavior disorder (RBD) at baseline. A decrease in STAI total score over time was predicted by a higher baseline score on the 15-item Geriatric Depression Scale, compulsive behavior at baseline and a family history of PD.
CONCLUSIONS: More severe baseline anxiety was associated with compulsive behavior and depressive symptoms. These symptoms had a parallel course, showing a decrease over time. An increase in anxiety was predicted by older age, worse cognitive functioning and the presence of RBD. Our findings, when replicated in a sample of PD patients in a more advanced disease stage, could provide starting points for prevention of anxiety in PD patients.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anxiety; Longitudinal; Neuropsychiatry; Parkinson's disease; Risk factor

Mesh:

Year:  2017        PMID: 28711192      PMCID: PMC5656500          DOI: 10.1016/j.parkreldis.2017.06.024

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  33 in total

1.  Symptomatology and markers of anxiety disorders in Parkinson's disease: a cross-sectional study.

Authors:  Albert F G Leentjens; Kathy Dujardin; Laura Marsh; Pablo Martinez-Martin; Irene H Richard; Sergio E Starkstein
Journal:  Mov Disord       Date:  2011-02-10       Impact factor: 10.338

2.  Course of psychiatric symptoms and global cognition in early Parkinson disease.

Authors:  Patricia de la Riva; Kara Smith; Sharon X Xie; Daniel Weintraub
Journal:  Neurology       Date:  2014-08-15       Impact factor: 9.910

Review 3.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 4.  Anxiety disorders in Parkinson's disease.

Authors:  Irene H Richard
Journal:  Adv Neurol       Date:  2005

5.  Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease.

Authors:  Daniel Weintraub; Andrew B Newberg; Mark S Cary; Andrew D Siderowf; Paul J Moberg; Galit Kleiner-Fisman; John E Duda; Matthew B Stern; David Mozley; Ira R Katz
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

6.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

7.  Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease.

Authors:  Daniel Weintraub; Staci Hoops; Judy A Shea; Kelly E Lyons; Rajesh Pahwa; Erika D Driver-Dunckley; Charles H Adler; Marc N Potenza; Janis Miyasaki; Andrew D Siderowf; John E Duda; Howard I Hurtig; Amy Colcher; Stacy S Horn; Matthew B Stern; Valerie Voon
Journal:  Mov Disord       Date:  2009-07-30       Impact factor: 10.338

8.  Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy.

Authors:  Mark A Stacy; Harald Murck; Kurt Kroenke
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-09-28       Impact factor: 5.067

9.  Screening for depression in Parkinson's disease: the performance of two screening questions.

Authors:  Sarah Baillon; Michael Dennis; Nelson Lo; James Lindesay
Journal:  Age Ageing       Date:  2013-10-16       Impact factor: 10.668

10.  REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson's disease.

Authors:  Michal Rolinski; Konrad Szewczyk-Krolikowski; Paul R Tomlinson; Kannan Nithi; Kevin Talbot; Yoav Ben-Shlomo; Michele Tm Hu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-11-01       Impact factor: 10.154

View more
  14 in total

1.  Depressive symptoms precede cognitive impairment in de novo Parkinson's disease patients: Analysis of the PPMI cohort.

Authors:  Jacob D Jones; Natalie E Kurniadi; Taylor P Kuhn; Sarah M Szymkowicz; Joseph Bunch; Elizabeth Rahmani
Journal:  Neuropsychology       Date:  2019-07-25       Impact factor: 3.295

Review 2.  The Relationship Between Anxiety Disorders and Parkinson's Disease: Clinical and Therapeutic Issues.

Authors:  Sandra Abou Kassm; Wadih Naja; Ramzi Haddad; Antoine Pelissolo
Journal:  Curr Psychiatry Rep       Date:  2021-03-03       Impact factor: 5.285

3.  Predictors of anxiety in Parkinson's disease: results from a 3-year longitudinal cohort study.

Authors:  Jessie S Gibson; Joseph L Flanigan; James T Patrie; W Alex Dalrymple; Madaline B Harrison
Journal:  Neurol Sci       Date:  2022-10-11       Impact factor: 3.830

Review 4.  Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Authors:  Stéphane Prange; Hélène Klinger; Chloé Laurencin; Teodor Danaila; Stéphane Thobois
Journal:  Drugs Aging       Date:  2022-06-16       Impact factor: 4.271

5.  Six-Year Follow-Up of Dysphagia in Patients with Parkinson's Disease.

Authors:  Ping Wang; Bo Wang; Xinhui Chen; Bing Xiong; Fangyao Xie; Sheng Wu; Yinshan Tang; Shuqi Chen; Xueping Ding; Peng Liu; Wei Luo
Journal:  Dysphagia       Date:  2021-11-26       Impact factor: 2.733

6.  The longitudinal associations between cognition, mood and striatal dopaminergic binding in Parkinson's Disease.

Authors:  Ece Bayram; Nikki Kaplan; Guogen Shan; Jessica Z K Caldwell
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2019-08-14

7.  Anxiety in Parkinson's Disease: Correlation with Depression and Quality of Life.

Authors:  Ankush Upneja; Birinder S Paul; Dinesh Jain; Rupesh Choudhary; Gunchan Paul
Journal:  J Neurosci Rural Pract       Date:  2021-03-24

8.  Prevalence and risk factors for depression and anxiety in Chinese patients with Parkinson disease.

Authors:  Shi-Shuang Cui; Juan-Juan Du; Rao Fu; Yi-Qi Lin; Pei Huang; Ya-Chao He; Chao Gao; Hua-Long Wang; Sheng-Di Chen
Journal:  BMC Geriatr       Date:  2017-11-22       Impact factor: 3.921

Review 9.  Accuracy of Rating Scales and Clinical Measures for Screening of Rapid Eye Movement Sleep Behavior Disorder and for Predicting Conversion to Parkinson's Disease and Other Synucleinopathies.

Authors:  Matej Skorvanek; Eva Feketeova; Monica M Kurtis; Jan Rusz; Karel Sonka
Journal:  Front Neurol       Date:  2018-05-25       Impact factor: 4.003

10.  Clinical Markers of Anxiety Subtypes in Parkinson Disease.

Authors:  Martinus P G Broen; A F G Leentjens; J T Hinkle; A J H Moonen; M L Kuijf; N M Fischer; K Perepezko; A Bakker; G M Pontone
Journal:  J Geriatr Psychiatry Neurol       Date:  2018-03-11       Impact factor: 2.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.